Thermo Fisher to develop CDx for Eli Lilly's RET inhibitor | Curetis to merge with OpGen | Razor Genomics to be purchased by OncoCyte
September 11, 2019
AACC SmartBrief
Business Perspective
Thermo Fisher to develop CDx for Eli Lilly's RET inhibitor
Thermo Fisher Scientific and Eli Lilly agreed to work together to develop a companion diagnostic for the latter's LOXO-292, a RET kinase inhibitor, using Thermo's Oncomine Dx Target test. The research aims to identify patients with non-small cell lung cancer and thyroid cancer whose tumors have RET alterations.
Clinical OMICs (9/9) 
LinkedIn Twitter Facebook Email
Curetis to merge with OpGen
OpGen is set to acquire Curetis GmbH, creating a combined company with commercial-stage molecular diagnostics and bioinformatics and a pipeline focused on antimicrobial resistance and infectious diseases. The transaction is expected to be completed in early 2020.
Clinical OMICs (9/6) 
LinkedIn Twitter Facebook Email
Razor Genomics to be purchased by OncoCyte
Razor Genomics, which markets a test to assess risk in early-stage lung cancer patients after surgery, will be acquired by OncoCyte. Razor will initially receive $10 million in cash for a 25% stake, plus an additional $1 million milestone payment for a recent positive coverage decision from the Centers for Medicare and Medicaid Services, and OncoCyte will have the option to purchase Razor's remaining shares.
Verdict Medical Devices (UK) (9/6) 
LinkedIn Twitter Facebook Email
Science Briefs
Methionine levels tied to diabetes development in children
Children with persistent elevated levels of the amino acid methionine in their blood developed type 1 diabetes, according to a study in Diabetologia. Researchers examined blood samples taken from 120 Finnish children from birth until age 3 and found that "children who progress to type 1 diabetes have a unique metabolic profile, which is, however, altered with the appearance of islet autoantibodies," adding that the findings could aid in earlier disease prediction.
Diabetes (UK) (9/6) 
LinkedIn Twitter Facebook Email
HIV tied to 80% increased risk for atrial fibrillation
A study in the Journal of the American College of Cardiology found that HIV is associated with heightened risk for atrial fibrillation that may lead to a stroke. Based on data from more than 17.3 million people, an 80% higher risk was seen for AFib in patients with HIV, which is comparable to the increased risk for AFib associated with hypertension.
MD Magazine online (9/9) 
LinkedIn Twitter Facebook Email
Increases in visceral fat may boost diabetes risk, study says
Each 1 kilogram increase in visceral fat may raise the risk of type 2 diabetes by seven-fold in women and 2.5 times in men, researchers reported in Nature Medicine. The study also found more than 200 genes that influence visceral fat, many related to food consumption and exercise.
United Press International (9/9) 
LinkedIn Twitter Facebook Email
Online Graduate Programs Designed for Your Career
Drexel's online programs in biotechnology, clinical research, drug discovery, infectious disease, immunology, and molecular medicine were developed to provide you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.
Business/Corporate Briefs
SkylineDx gets $21.9M investment to support melanoma test development
Dutch diagnostics firm SkylineDx will advance its melanoma test using $21.9 million it received from a private investor. The test is designed to predict the possibility of a melanoma patient's cancer metastasizing in lymph nodes without requiring a biopsy.
Verdict Medical Devices (UK) (9/3) 
LinkedIn Twitter Facebook Email
Specific Diagnostics gets investment for antibiotic susceptibility test
Investment firm Telegraph Hill Partners has provided $12.5 million to in vitro diagnostics firm Specific Diagnostics. Specific intends to use the money to support the marketing of its antibiotic susceptibility test, the Reveal platform.
FinSMEs (9/6) 
LinkedIn Twitter Facebook Email
Conference: 2019 Point of Care Testing Boot Camp and Beyond: Communicating, Connecting, and Collaborating
Don't miss the third annual POCT Boot Camp where you will gain skills and tools to successfully communicate, connect, and collaborate with POCT staff and management in any patient care setting. November 8, 2019, Pittsburgh, Pa.
LinkedIn Twitter Facebook Email
AACC Point-of-Care Testing Professional Certification (CPP)
Apply today to stand out as a point-of-care testing professional that has gone above and beyond to demonstrate proficiency in one of the fasting growing disciplines within laboratory medicine. Application deadline: September 16, 2019
LinkedIn Twitter Facebook Email
Learn more about AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry | JALM
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Contributing Editor  -  Genna Rollins
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information